Gregory Morrison Net Worth

The estimated Net Worth of Gregory Morrison is at least $5.66 Milion dollars as of 10 November 2017. Gregory Morrison owns over 92,140 units of Wright Medical NV stock worth over $1,063,930 and over the last 9 years Gregory sold WMGI stock worth over $4,592,407.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Gregory Morrison WMGI stock SEC Form 4 insiders trading

Gregory has made over 6 trades of the Wright Medical NV stock since 2016, according to the Form 4 filled with the SEC. Most recently Gregory sold 92,140 units of WMGI stock worth $2,183,718 on 10 November 2017.

The largest trade Gregory's ever made was selling 92,140 units of Wright Medical NV stock on 10 November 2017 worth over $2,183,718. On average, Gregory trades about 16,141 units every 44 days since 2015. As of 10 November 2017 Gregory still owns at least 35,488 units of Wright Medical NV stock.

You can see the complete history of Gregory Morrison stock trades at the bottom of the page.

What's Gregory Morrison's mailing address?

Gregory's mailing address filed with the SEC is 10801 NESBITT AVNEUE S., , BLOOMINGTON, MN, 55437.

Insiders trading at Wright Medical NV

Over the last 9 years, insiders at Wright Medical NV have traded over $526,674,381 worth of Wright Medical NV stock and bought 118,654 units worth $2,654,459 . The most active insiders traders include Sean Carney, Elizabeth H Weatherman a Holdings Cooperatief U.A.Wa.... On average, Wright Medical NV executives and independent directors trade stock every 9 days with the average trade being worth of $4,402,563. The most recent stock trade was executed by Tim Lanier on 17 August 2020, trading 951 units of WMGI stock currently worth $28,644.

What does Wright Medical NV do?

Wright Medical Group NV engages in the provision of medical device products. It operates through the following segments: U.S. Lower Extremities and Biologics; U.S. Upper Extremities; International Extremities and Biologics; and Corporate. The U.S. Lower Extremities and Biologics includes the sale of its lower extremities products, such as joint implants and bone fixation devices for the foot and ankle; and biologics products used to support treatment of damaged or diseased bone, tendons, and soft tissues or to stimulate bone growth. The U.S. Upper Extremities segment focuses on joint implants and bone fixation devices for the shoulder, elbow, wrist, and hand; and products used across several anatomic sites to mechanically repair tissue-to-tissue or tissue-to-bone injuries, and other ancillary products. The International Extremities and Biologics segment covers all lower and upper extremities products, as well as associated biologics products. The Corporate segment reflects general and administrative expenses not specifically associated with other segments. The company was founded by Frank O. Wright in 1950 and is headquartered in Amsterdam, the Netherlands.

Complete history of Gregory Morrison stock trades at Wright Medical NV

Wright Medical NV executives and stock owners

Wright Medical NV executives and other stock owners filed with the SEC include:

• Robert Palmisano,
  President and Chief Executive Officer, Executive Director
• Peter Cooke,
  President, Emerging Markets, Australia and Japan
• Lance Berry,
  Executive Vice President, Chief Financial and Operations Officer
• Kevin Cordell,
  Executive Vice President, Chief Global Commercial Officer
• Andrew Morton,
  Senior Vice President, Chief Human Resources Officer
• James Lightman,
  Senior Vice President, General Counsel and Secretary
• Barry Regan,
  Senior Vice President, Operations
• Jason Asper,
  Senior Vice President, Chief Digital Officer
• David Stevens,
  Non-Executive Independent Chairman of the Board
• Kevin O'Boyle,
  Non-Executive Independent Director
• Elizabeth Weatherman,
  Non-Executive Independent Director
• John Miclot,
  Non-Executive Independent Director
• Richard Wallman,
  Non-Executive Independent Director
• Gary Blackford,
  Non-Executive Independent Director
• Amy Paul,
  Non-Executive Independent Director
• James Mackin,
  Non-Executive Independent Director
• Steven Wallace,
  President, International
• Kevin Smith,
  Senior Vice President, Quality and Regulatory
• Julie Dewey,
  Senior Vice President, Chief Communications Officer
• Timothy Lanier,
  President, Upper Extremities
• Patrick Fisher,
  President, Lower Extremities
• Julie Andrews,
  Senior Vice President, Global Finance
• Jennifer Walker,
  Senior Vice President, Process Improvement
• J. Porter,
  Senior Vice President, Chief Compliance Officer
• Tim Lanier,
  President, Upper Extremities
• Sean Carney,
  Director
• William L. Jr Griffin,
  SVP GM BioMimetic Therapeutics
• Terry M. Rich,
  President, Upper Extremities
• Gregory Morrison,
  Sr. VP, Human Resources
• Robert P. Iii Burrows,
  SVP, Supply Chain
• David H Mowry,
  EVP and COO
• Ummersen Gordon Van,
  Sr. VP, Product Delivery
• Holdings Cooperatief U.A.Wa...,
  
• Alain Tornier,
  Director
• Richard B Emmitt,
  Director
• Kevin M Klemz,
  Sr. VP, CLO and Secretary
• Shawn Mc Cormick,
  Chief Financial Officer
• Medical Group N.V. Wright,
  President, Lower Extremities